FendX Announces LOI with Sinelabs LLC to Pursue Sales and Distribution Agreement for FendX's Future Surface Protection Products

In This Article:

Oakville, Ontario--(Newsfile Corp. - November 13, 2024) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the "Company" or "FendX"), a nanotechnology company developing surface protection coatings is pleased to announce that the Company has entered into a letter of intent (the "LOI") dated November 12, 2024 with Sinelabs LLC ("Sinelabs"), a South Carolina based company, to enter into a sales and distribution agreement for the Company's potential future products that protect surfaces from contamination.

Sinelabs is a private sales and distribution company currently focused on developing and distributing innovative water treatment solutions to enhance water quality by neutralizing bacteria and pathogens, and reduce scale and mineral buildup. In the United States, Sinelabs has an established sales and distribution network that overlaps with target markets where FendX anticipates selling and distributing their future surface protection products, including healthcare, hospitality and senior living facility industries. The Company believes this overlap represents a financially efficient sales and distribution opportunity for both companies.

Pursuant to the terms of the non-binding LOI, both Sinelabs and FendX have expressed interest to further explore the engagement of Sinelabs as a non-exclusive distributor of FendX future products in the United States. The parties intend to negotiate a sales and distribution agreement and subsequent product distribution addendums for FendX's future products in the infection disease control area (each referred to as the "Product"), should any such Product be commercially developed and approved for distribution in the United States that the parties agree to distribute. At this time, the engagement of Sinelabs as a distributor remains subject to negotiation and execution of a definitive sales and distribution agreement and execution of product addendum agreements, which addendums would be subject to the Company establishing a supply chain, successful product commercial development and receiving approval for distribution.

Dr. Carolyn Myers, CEO of FendX states, "We believe this is the opportune time to develop distribution relationships, given the strides we are making to further the development of our nanotechnology products. REPELWRAP™ film is our lead product in development and we anticipate it will soon enter real world testing, advancing our product commercialization plan." Dr. Myers continues, "We believe that Sinelabs will be an ideal distribution partner based on their selling and distribution experience and the network they continue to build in industries we believe are relevant to our surface protection products in development."